口服食物挑战试验发现许多婴儿对花生不过敏
Oral Food Challenge Clears Many Infants Thought to Have Peanut Allergy
一项来自澳大利亚的多中心研究发现,34.8%的婴儿在口服食物挑战试验中对花生不过敏,这表明许多被怀疑对花生过敏的婴儿实际上并非过敏。研究认为,准确通过口服食物挑战试验确认婴儿的过敏情况可以减少误诊并避免不必要的治疗。
研究发现,许多被怀疑对花生过敏的婴儿实际上并非过敏,这可能改变过敏治疗策略。
— Researchers say biomarkers and clinical history of reaction alone aren't enough for diagnosis
November 6, 2026 • 3 min read
- In a multicenter study from Australia, 34.8% of babies with a prior reaction and sensitization to peanut were found to tolerate peanut on an oral food challenge test and could be considered non-allergic by this gold-standard test.
- Oral food challenge is not standard clinical practice for infants with prior reaction and sensitization to peanut but should be, according to the researchers.
- Accurately confirming allergy via oral food challenge in infants could reduce the burden of allergy misdiagnosis and help avoid unnecessary treatment.
More than a third of infants thought to be allergic to peanuts were not actually allergic, an oral food challenge study showed.
With the aim of treating peanut allergy among babies who reacted to peanut before 1 year of age and had a positive skin prick or blood test, 34.8% who were subject to an oral food challenge (OFC) to set the dose for oral immunotherapy came up negative and could be considered non-allergic by this gold-standard test.
That rate was "far higher than expected," noted Kirsten Perrett, MBBS, PhD, of Murdoch Children's Research Institute at the Royal Children's Hospital in Melbourne, Australia, and colleagues in the Journal of Allergy and Clinical Immunology: In Practice.
Typically, a history of reaction plus sensitization is considered enough for diagnosis of peanut allergy, and children are sent home with instructions to avoid peanut products. While a majority of children outgrow milk or egg allergies, only about a quarter to a third of children outgrow peanut allergies without treatment by age 6 years.
The current results potentially indicate that some infants have a transient immune response to the allergen that resolves quickly (an average of 6 months between initial reaction and OFC in this study) or doesn't result in ongoing reactions upon further exposure, Perrett and team said.
Determining that early allows reintroduction of peanut in infancy, which may change the trajectory of peanut allergy and reduce the burden of food allergy, independent of an oral immunotherapy program, they added.
OFC "should be routinely considered in infant peanut allergy evaluation regardless of the proposed management strategy (immunotherapy or allergen avoidance)," Perrett and colleagues argued. "Biomarkers and clinical history alone are insufficient to diagnose peanut allergy in this age group."
That hasn't been the case "for a variety of reasons including carer or clinician concerns regarding safety, time, and/or resource constraints, or the belief that an OFC is unnecessary when there is a clear clinical history of reaction and a positive test of sensitization," they wrote.
With regard to safety, their study showed 61 cases of anaphylaxis during the 778 threshold OFCs (7.8%), which is a higher rate than in the conventional use of OFCs for cases in which diagnosis is unclear from clinical history or the allergy is suspected to be outgrown. While that means these OFCs should be performed in centers with appropriate medical support, the trade-off is worthwhile, Perrett and colleagues suggested.
"Accurately confirming allergy via OFC in infants can reduce the burden of allergy for patients, families, and society through misdiagnosis, and before the commencement of OIT [oral immunotherapy], it can help avoid unnecessary treatment," they pointed out.
The Allergy Development to an Accelerated Pathway to Tolerance (ADAPT) OIT program was a partnership with 10 major pediatric hospitals in five states across Australia to develop and implement the first standardized nationwide model of care for food allergy treatment.
The program was to enroll all infants presenting with a clinical history of an immunoglobulin E (IgE)-mediated allergic reaction to peanut before age 12 months and evidence of sensitization from a peanut skin prick test wheal of at least 3 mm or a peanut-specific IgE or Ara h 2-specific IgE of at least 0.35 kUA/L.
The 59 infants whose reaction to peanut had been anaphylaxis (Consortium for Food Allergy Research grade 3) could go straight to oral immunotherapy. Notably, 14 of the 29 patients in this group (48.3%) who had a threshold OFC did not react and were deemed tolerant to peanut.
Babies with an initial grade 1 to 2 reaction to peanut were to undergo OFC to peanut before commencing OIT both to confirm the diagnosis of peanut allergy and to determine peanut reaction threshold to inform the OIT starting dose. The OFC used a commercially available peanut flour (PB2).
Median age at OFC was 13 months, and it took a median 3 months from the time of initial reaction to the first allergy assessment in the allergy clinics.
Skin prick and blood test results were both significantly linked to a positive OFC (P<0.001) but did not predict the reaction threshold or severity.
来源:MedPage Today · medpagetoday.com